Literature DB >> 34206290

Multidisciplinary Approach for Hypothalamic Obesity in Children and Adolescents: A Preliminary Study.

Daniele Tessaris1, Patrizia Matarazzo1, Gerdi Tuli1, Antonella Tuscano2, Ivana Rabbone1, Alessandra Spinardi3, Antonella Lezo4, Giorgia Fenocchio5, Raffaele Buganza1, Luisa de Sanctis1.   

Abstract

Hypothalamic obesity (HO) is delineated by an inexorable weight gain in subjects with hypothalamic disorder (congenital or acquired). The aim of the present study was to evaluate the effect of a multidisciplinary approach on weight trend and metabolic outcome in children and adolescents with hypothalamic disease who were overweight or obese. Thirteen patients (aged 8.1-16.1 years) received a personalized diet, accelerometer-based activity monitoring, and psychological assessment. Height, weight, body mass index (BMI), and serum metabolic parameters were assessed at baseline (T0) and after six months (T1). Metformin was introduced at T1 in four subjects who were then re-evaluated after six months (T2). At T1, weight gain was significantly reduced compared with T0 (0.29 ± 0.79 kg/month vs. 0.84 ± 0.55 kg/month, p = 0.03), and weight standard deviation score (SDS) and BMI SDS did not change significantly, as serum metabolic parameters. The four subjects treated with metformin showed a reduction of weight SDS and BMI SDS at T2. In conclusion, patients treated with our multidisciplinary approach showed, after 6 months, favorable results characterized by decreased weight gain and stabilization of weight SDS and BMI SDS in a condition usually characterized by inexorable weight gain. However, further analysis, larger cohorts, and longer follow-up are needed to confirm these preliminary data.

Entities:  

Keywords:  BMI; hypothalamic obesity; metformin; weight gain

Year:  2021        PMID: 34206290     DOI: 10.3390/children8070531

Source DB:  PubMed          Journal:  Children (Basel)        ISSN: 2227-9067


  40 in total

1.  Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence.

Authors:  B Bülow; R Attewell; L Hagmar; P Malmström; C H Nordström; E M Erfurth
Journal:  J Clin Endocrinol Metab       Date:  1998-11       Impact factor: 5.958

Review 2.  Hypothalamic Obesity: Prologue and Promise.

Authors:  M Jennifer Abuzzahab; Christian L Roth; Ashley H Shoemaker
Journal:  Horm Res Paediatr       Date:  2019-03-18       Impact factor: 2.852

3.  Hyperphagia in children with craniopharyngioma is associated with hyperleptinaemia and a failure in the downregulation of appetite.

Authors:  C Roth; B Wilken; F Hanefeld; W Schröter; U Leonhardt
Journal:  Eur J Endocrinol       Date:  1998-01       Impact factor: 6.664

4.  Triiodothyronine supplementation for hypothalamic obesity.

Authors:  J K Fernandes; M J Klein; Joann L Ater; John F Kuttesch; Rena Vassilopoulou-Sellin
Journal:  Metabolism       Date:  2002-11       Impact factor: 8.694

5.  Treatment of Hypothalamic Obesity with Dextroamphetamine: A Case Series.

Authors:  Christian Denzer; Friederike Denzer; Belinda S Lennerz; Heike Vollbach; Robert H Lustig; Martin Wabitsch
Journal:  Obes Facts       Date:  2019-03-07       Impact factor: 3.942

6.  Weight gain in craniopharyngioma--a model for hypothalamic obesity.

Authors:  Alexandra Ahmet; Susan Blaser; Derek Stephens; Sharon Guger; James T Rutkas; Jill Hamilton
Journal:  J Pediatr Endocrinol Metab       Date:  2006-02       Impact factor: 1.634

Review 7.  Optimal cut-off values for the homeostasis model assessment of insulin resistance (HOMA-IR) and pre-diabetes screening: Developments in research and prospects for the future.

Authors:  Qi Tang; Xueqin Li; Peipei Song; Lingzhong Xu
Journal:  Drug Discov Ther       Date:  2015-12

8.  Treatment of hypothalamic obesity with caffeine and ephedrine.

Authors:  Frank L Greenway; George A Bray
Journal:  Endocr Pract       Date:  2008-09       Impact factor: 3.443

9.  Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial.

Authors:  Robert H Lustig; Pamela S Hinds; Karen Ringwald-Smith; Robbin K Christensen; Sue C Kaste; Randi E Schreiber; Shesh N Rai; Shelly Y Lensing; Shengjie Wu; Xiaoping Xiong
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

10.  GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases.

Authors:  Flavius Zoicas; Michael Droste; Bernhard Mayr; Michael Buchfelder; Christof Schöfl
Journal:  Eur J Endocrinol       Date:  2013-04-15       Impact factor: 6.664

View more
  2 in total

Review 1.  Treatment of Acquired Hypothalamic Obesity: Now and the Future.

Authors:  Paul Dimitri
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-06       Impact factor: 6.055

2.  Effects of a Mixed Exercise Program on Overweight and Obese Children and Adolescents: A Pilot, Uncontrolled Study.

Authors:  Roberto Pippi; Gabriele Mascherini; Pascal Izzicupo; Vittorio Bini; Carmine Giuseppe Fanelli
Journal:  Int J Environ Res Public Health       Date:  2022-07-28       Impact factor: 4.614

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.